Similar Search Results

Fair prices for medicines? : exploring competent authorities’ and public payers’ preferences on pharmaceutical policies

Vogler, Sabine - In: Empirica : journal of european economics 46 (2019) 3, pp. 443-469

Persistent link: https://www.econbiz.de/10012242289

Pharmaceutical regulation in Europe and its impact on corporate R&D

Eger, Stephan; Mahlich, Jörg C. - In: Health economics review 4 (2014) 23, pp. 1-9

Objectives: Many European countries regulate the markets for prescription drugs in order to cope with rising health expenditures. On the other hand, regulation distorts incentives to invest in pharmaceutical R&D. This study aims at empirically assessing the impact of regulation on pharmaceutical...

Persistent link: https://www.econbiz.de/10010526909

The impact of the entry of biosimilars : evidence from Europe

Scott Morton, Fiona; Stern, Ariel D.; Stern, Scott - 2017

Persistent link: https://www.econbiz.de/10011708133

Pharmaceutical marketing return-on-investment: a European perspective

Rod, Michel; Ashill, Nicholas J.; Carruthers, Janet - In: International journal of pharmaceutical and healthcare … 1 (2007) 2, pp. 174-189

Persistent link: https://www.econbiz.de/10003937245

European pharmaceutical prices, 1964-74

Cooper, Michael H. - 1975

Persistent link: https://www.econbiz.de/10001681733

Pharmaceutical Pricing in Europe : Is Differential Pricing a Win-Win Solution?

Garau, Martina - 2015

to health care, including pharmaceuticals. Given pressure on public budgets and rising expenditure for healthcare …, national governments have introduced mechanisms to regulate healthcare services provision and set prices of pharmaceuticals. As … pharmaceuticals and, in particular, its price-setting system. The bill endorsed by the German parliament in late 2010 will …

Persistent link: https://www.econbiz.de/10013018181

Anticompetitive Marketing in the Context of Pharmaceutical Switching in Europe

Domeij, Bengt - 2013

The article deals with the intersection between competition law rules on abuse of a dominant position and switching strategies employed by pharmaceutical originator companies. Switching is also known as ever-greening, product hopping or product life cycle strategies. It is one of the most...

Persistent link: https://www.econbiz.de/10013077034

European Pharmaceutical Price Regulation, Firm Profitability, and R&D Spending

Golec, Joseph H. - 2006

EU countries closely regulate pharmaceutical prices whereas the U.S. does not. This paper shows how price constraints affect the profitability, stock returns, and R&D spending of EU and U.S. firms. Compared to EU firms, U.S. firms are more profitable, earn higher stock returns, and spend more on...

Persistent link: https://www.econbiz.de/10012465985

The EU's open strategic autonomy in the field of pharmaceuticals : overcoming import dependencies for antibiotics through the EU authority HERA

Bayerlein, Michael - Stiftung Wissenschaft und Politik - 2023

identifying and eliminating import dependencies in the field of pharmaceuticals. HERA’s work thus aligns with current EU efforts …

Persistent link: https://www.econbiz.de/10013540432

Which policies for vaccine innovation and delivery in Europe?

Dewatripont, Mathias - 2022 - Revised, April 2022

Persistent link: https://www.econbiz.de/10013208383

1
2
3
4
5
6
7
8
9
10
Next
Last